Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo of radioactive drug and chemo tackles Hard-to-Treat breast cancer

NCT ID NCT06247995

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabine). The study has two parts: first, finding safe doses, and second, checking if the combination shrinks tumors. Only 20 participants are enrolled, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lutetium NeoB (a radioactive drug) and capecitabine (chemotherapy)
What this could lead to
If it works, this could offer a new treatment option for people with advanced breast cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early, small trial (20 people) focused on safety and dosing, so it may not lead to a proven treatment. The radioactive drug and chemo can cause side effects like fatigue, low blood counts, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Mayo Clinic - Rochester

    Rochester, Minnesota, 55905, United States

  • Novartis Investigative Site

    Darlinghurst, New South Wales, 2010, Australia

  • Novartis Investigative Site

    Malvern, Victoria, 3144, Australia

  • Novartis Investigative Site

    Toronto, Ontario, M4N 3M5, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H3T 1E2, Canada

  • Novartis Investigative Site

    Tianjin, 300300, China

  • Novartis Investigative Site

    Grenoble, 38043, France

  • Novartis Investigative Site

    Saint-Herblain, 44805, France

  • Novartis Investigative Site

    Villejuif, 94800, France

  • Novartis Investigative Site

    Erlangen, 91054, Germany

  • Novartis Investigative Site

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    Delft, South Holland, 2625 AD, Netherlands

  • Novartis Investigative Site

    Porto, 4200-072, Portugal

  • Novartis Investigative Site

    Singapore, 168583, Singapore

  • Novartis Investigative Site

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • UCLA Medical Center

    Los Angeles, California, 90095, United States

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas, 77030, United States

  • University Of Wisconsin

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.